Skip to main content
Premium Trial:

Request an Annual Quote

Naveed Shams

Premium
Opko Health said this week that it has appointed Naveed Shams as its chief medical officer and senior vice president of research and development.
 
Before joining Opko, Shams worked at Genentech where he oversaw development of that company’s wet age-related macular degeneration drug Lucentis. Opko is developing its own AMD treatment, an RNAi drug called bevasiranib, which is under phase III development (see RNAi News, 9/6/2007).

 

Shams holds an MD from Dow Medical College in Pakistan and a PhD in microbiology and immunology from the University of South Carolina.

The Scan

mRNA-Based Vaccine on the Way in China

China may soon have its own mRNA-based vaccine, according to Nature News.

Arranged Killing, Fraud Alleged by Prosecutors

The Wall Street Journal reports that prosecutors allege that the co-founder of a biotech arranged to have a business associate who threatened to expose him as a fraud killed.

Whirlwind Decade of CRISPR

The New York Times looks back at the 10 years since the University of California, Berkeley's Jennifer Doudna and her colleagues published their CRISPR paper.

PNAS Papers on Blue Cone Monochromacy Structural Variants, HIV-1 Mutant, T-ALL

In PNAS this week: structural variants linked to blue cone monochromacy, HIV-1 variants affecting the matrix protein p17, and more.